Abdul Latif Jameel Health & JIMCO participate in Cellarity US$ 123m Series B round to pioneer a new approach to drug discovery

• Cellarity launched in 2017, within Flagship Labs to create drugs which treat disease by changing the way cells behave, rather than targeting specific molecular targets
• Founded in 2020, Abdul Latif Jameel Health was created as a response to the ongoing global disparity in access to modern medical care, most notably across emerging economies of the developing world
•  The JIMCO Life Sciences Fund, is a dedicated fund of the Jameel Investment Management Company actively investing in innovative, early-stage and breakthrough ventures and technology, aiming to positively shape the future of health

Dubai: June 1, 2021

The Jameel Investment Management Company (JIMCO), the global investment arm of the Jameel Family, confirmed that it is one of the investors in the recent US$ 123 million Series B funding round for Cellarity – an American life sciences company founded by Flagship Pioneering in 2017, to develop a new method of drug discovery targeting cell behavior.

The contribution to the round from JIMCO’s dedicated JIMCO Life Sciences Fund,, sits alongside those from funds and accounts managed by BlackRock, The Baupost Group, Banque Pictet together with other investors, and Flagship Pioneering.

This initial investment is part of the ongoing strategic vision in collaboration with Abdul Latif Jameel Health to pursue targeted Investments in breakthrough thinking and emergent health technologies that will enable more globally inclusive healthcare through accelerating access to modern medical therapies for those who need it most.

Akram Bouchenaki, Chief Executive Officer, Abdul Latif Jameel Health, said: “Our mission is to partner and support innovators within the medical world that are disrupting existing practices and pushing for wider availability of healthcare throughout the world.  The synergy with Cellarity and their breakthrough thinking are clear to the Abdul Latif Jameel Health team, and our contribution to helping pioneer this new approach to drug discovery is aligned with the values of Abdul Latif Jameel Health and the Jameel Family.”

Cellarity’s medicines are developed to address disease at the level of the cell and are not aimed at single molecular targets, the approach pursued in many traditional drug discoveries.

“We are entering the era of generative biology and the ability to create medicines with much more predictability and intentionality,” said Fabrice Chouraqui, CEO-Partner, Flagship Pioneering and CEO, Cellarity. “Cellarity’s platform, combining biology, computation and technology represents a dramatic rearchitecting of the current drug discovery paradigm toward this cell-centric approach.”

---

Notes to Editors 

About Abdul Latif Jameel Health 

Backed by Abdul Latif Jameel, one of the most respected diversified family businesses and investors with a 75-year heritage, deep roots, and established networks alongside a multi-sector presence in 30 countries across six continents, Abdul Latif Jameel Health is uniquely positioned as a trusted partner in realizing major innovations and opportunities in the healthcare world.   

Abdul Latif Jameel Health reflects the Jameel family’s long-established commitment to innovating for a better future through Community Jameel, an international organization supporting science and technology-led solutions to global challenges.  Community Jameel and MIT co-founded the Abdul Latif Jameel Clinic for Machine Learning in Health (Jameel Clinic) in September 2018 – which has rapidly become the very epicenter of AI and healthcare at MIT – and the Abdul Latif Jameel Institute for Disease and Emergency Analytics (Jameel Institute) co-founded with Imperial College London, in October 2019, using novel data analytics to reduce global risk of preventable disease most recently including the 2020 COVID-19 pandemic, and strengthening health systems in the most fragile settings.

Abdul Latif Jameel Health takes this commitment into the commercial environment addressing tangible real-world needs today, for a better tomorrow.  It is focused on health care inclusion in the global south, accelerating access to modern medical care for those who need it most by opening up/growing new markets for distribution of existing solutions and investing in the future of MedTech.

JIMCO actively invests in innovative, early-stage and breakthrough ventures and technology, aiming to positively shape the future of core industries driving the global economy through its’ investments that span medical and healthcare industries, from pharmaceuticals and vaccines to cutting-edge medical technology, along with emergent technologies across FinTech, InsurTech, electric vehicles and future mobility solutions.

For further information, visit: https://aljhealth.com and our brand video here.
Media Contact:  Email aljhealth@edelman.com or telephone: +971 54 996 9935 (GMT +4 hours UAE) 

About Abdul Latif Jameel 

Abdul Latif Jameel is a global investor and diversified, private family owned business celebrating its 75th anniversary in 2020.  It is comprised of a number of independent entities across a number of major industry sectors including: passenger vehicles; commercial vehicles and equipment; logistics; engineering and manufacturing; financial services; energy and environmental services, health; land and real estate: consumer products and advertising and media.  Strong trusted networks and long-established relationships make Abdul Latif Jameel a powerful business and investment collaborator across the world.  It currently has a presence in more than 30 countries on six continents and employs more than 11,000 people of over 40 nationalities. 
For further information, visit: https://aljhealth.com. 
For press inquiries, contact media@alj.ae, or call +971 4 448 0906 (GMT +4 hours UAE) 

About Cellarity

Cellarity’s mission is to bring breakthrough medicines to patients by completely redefining the way drugs are discovered.  Founded by Flagship Pioneering in 2017, Cellarity is designing medicines against the cell as opposed to a single molecular target.  The Company has developed a unique combination of expertise across system and network biology, high-resolution data, and machine learning to unlock treatments in a large number of therapeutic areas.  For more information, visit: cellarity.com  

For media enquiries, please contact:

Kent Holland, +1 917 561-9684 / cellaritymedia@kivvit.com 

Copyright Notice and Disclaimer

© Meddist Company Ltd. (Abdul latif Jameel Health).  All rights fully reserved.  The Abdul Latif Jameel name, and the Abdul Latif Jameel logotype and pentagon-shaped graphic are trademarks, or registered trademarks of Abdul Latif Jameel IPR Company Limited. The term “Abdul Latif Jameel” refers broadly to several distinct, separate and independent legal entities. Abdul Latif Jameel is not itself a corporate entity, association or conglomerate run by an overarching parent company but merely refers to a group of distinct and wholly separate legal entities that are collectively referred to as Abdul Latif Jameel. Abdul Latif Jameel is not a corporate group as defined in section 1161(5) of the Companies Act 2006.

This document may contain forward-looking statements.  Forward-looking statements are statements regarding matters other than historical fact, such as future results, events, activities, developments or circumstances or the beliefs, plans or expectations of Abdul Latif Jameel Health or Abdul Latif Jameel entities or their respective managements.

Forward-looking statements often can be identified by the use of words such as ‘expect’, ‘project’, ‘anticipate’, ‘plan’, ‘estimate’, ‘believe’, ‘predict’, ‘intend’, ‘potential’, ‘possible’, ‘probable’, ‘likely’, ‘forecast’, ‘guidance’, ‘outlook’, ‘goal’, ‘target’, ‘may’, ‘will’, ‘should’ or ‘could’ or other similar terms or phrases.  However, the absence of such words does not mean that a particular statement is not forward looking.

Forward-looking statements are based on expectations and assumptions at the time of such statements and are subject to numerous risks and uncertainties, many of which are outside the control of Abdul Latif Jameel Health or Abdul Latif Jameel entities.  Should any of such expectations or assumptions prove incorrect, or should any of such risks or uncertainties materialize, actual future results, events, activities, developments or circumstances may differ materially from those expressed in or implied by forward-looking statements. 

Further, any forward-looking statement speaks only as of the date on which it is made, and neither Abdul Latif Jameel Health nor Abdul Latif Jameel assumes, and hereby disclaims, any obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise.  All forward-looking statements made by Abdul Latif Jameel Health, Abdul Latif Jameel, or by any person on behalf of any of them, whether communicated in writing, electronically or orally, are qualified in their entirety by the foregoing cautionary statements.

---